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ment with statins, suggesting a suboptimal use of resources. We
studied the drug costs associated with overtreatment and the
costs to eliminate undertreatment with statins in an elderly pop-
ulation. METHODS: Overtreatment and undertreatment with
statins were ascertained using current Dutch cholesterol man-
agement guidelines. Data were acquired from the Rotterdam
Study. This is a population-based prospective cohort study,
which started in 1990 with 7983 participants of at least 55 years
of age. This analysis focused on primary prevention of cardio-
vascular disease (CVD) excluding subjects with a history of car-
diovascular disease. To estimate patterns of medication use in
daily practice pharmacy records were obtained. RESULTS: From
the 3251 participants 464 (14%) were still alive on January 1st
2002, had no history of CVD and were undertreated. Of the 
565 participants starting statin treatment 389 (69%) were
overtreated according to the same guidelines. After projection on
the general Dutch population, the absolute costs for overtreat-
ment with statins in 2005 were estimated to be approximately
23 million Euros (Uncertainty limits (UL): 19–28 million Euro),
while the cost to eliminate undertreatment were also 23 million
Euros (UL: 19–28 million Euros). CONCLUSION: In conclu-
sion, when considering only drug costs reallocation of resources
used for statin treatment from those overtreated to those under-
treated could lead to a more efﬁcient use of resources.
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OBJECTIVES: To identify key factors determining therapeutic
decision making concerning coronary artery disease treatment in
the GPs’ and specialists’ practices. To establish role of economic
factors related. METHODS: A survey was conducted on the rep-
resentative sample of Polish physicians (184 GPs and 63 spe-
cialists in the outpatient clinics) dealing with coronary artery
disease (CAD) patients. Data were obtained with the aid of a
speciﬁc questionnaire, including 6 items completed by doctor.
RESULTS: Choosing the treatment for a CAD patient, 75% of
the GPs and specialists have taken drugs’ efﬁcacy into consider-
ation at ﬁrst. Safety of treatment (GPs 9.8% and specialists
12.7% respectively) and adherence to guidelines (9.2%; 9.5%)
were rarely considered as main factors. One third of the GPs and
specialists declared that unbearable drugs’ costs constituted the
most frequent reason for treatment discontinuation. The adverse
events (20.6% and 20.1%) and poli-therapy (20.6% and 19.6%)
were the next reasons cited. Treatment with the lowest priced
drugs (75%; 74%) and those medicines administered once a day
(75%; 71%) were described as two best ways of compliance
improvement. The most important factors leading to the change
of treatment were insufﬁcient efﬁcacy (88%) and adverse events
(81%). 70% of GPs and 74% of specialists declared, that every
third patient talked about economic issues of treatment (co-
payment, costs of diagnostic procedures and additional doctors’
consultations). Only 31.5% of the GPs and 41.3% of specialists
indicated an inﬂuence on the quality of life among the top three
most important factors determining a therapeutic decision.
CONCLUSIONS: Factors determining therapeutic decisions in
the CAD patients are quite similar among the GPs and special-
ists. Efﬁcacy and safety of therapy represented factors commonly
reported by the GPs as well as specialists. Unbearable cost of
pharmacotherapy was considered as one of the main causes
leading to treatment discontinuation and incompliance.
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OBJECTIVE: Regular testing of total cholesterol (TC), high-
density lipoprotein cholesterol (HDL-C) and triglycerides (TG)
is important for effective lipid management. Our objective was
to examine frequency of lipid testing and to assess predictors of
lipid testing frequency in UK patients newly initiated on statins
over a one year period. METHODS: This was a retrospective
cohort study performed using the UK General Practice Research
Database. Patients aged ≥35 years were included if they received
their ﬁrst ever statin between Jan-2000 and Dec-2004 and had
at least one TC, HDL-C or TG test conducted in the one year
period before statin initiation. Lipid tests performed after statin
initiation were counted until the earliest of either one-year
follow-up or statin discontinuation date plus 30 days. Poisson
regression was used to assess pre-initiation factors associated
with testing frequency for each lipid following statin initiation.
RESULTS: 57,296 patients received at least one TC, HDL-C or
TG at baseline and had one year of follow-up after statin initi-
ation. On average, patients received 1.3 ± 1.0 TC tests. However,
22.7% patients did not receive a single TC test after starting on
statins. The mean number of tests per patient for HDL-C and
TG was 0.9 ± 1.0 but 44.3% and 39.1% of patients did not
receive a single HDL-C and TG test, respectively. In the multi-
variate analysis, high cardiovascular risk [OR, 1.04; 95% CI,
1.01–1.07] and baseline TC ≥6.2 mmol/L [OR, 1.1; 95% CI,
1.06–1.18, compared with TC <5.0 mmol/L] were associated
with TC testing frequency. CONCLUSION: Higher cardiovas-
cular risk and higher baseline TC were associated with TC
testing within the ﬁrst year following statin initiation. Lack of
TC testing in approximately 2 in 10 UK patients during that
period and infrequent HDL-C and TG testing may prove as bar-
riers towards effective lipid management.
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OBJECTIVES: To develop a care map for Congestive Heart
Failure (CHF) in the UK, covering diagnosis, progression and
treatment of patients, focussing on points of interaction with the
UK NHS. METHODS: Available literature was searched for
national and local clinical guidelines and treatment algorithms
for CHF in the UK. Ten experts were consulted to validate and
complete the dataset. An interactive 1-year care map of CHF care
in the UK was then developed in MS Excel. New York Heart
Association (NYHA) bands I to IV were used to group patients
by disease severity and costs were estimated from an NHS per-
spective for 2005. Patient transition between hospital (including
readmissions), home and nursing home was modelled. Possible
surgical interventions were: heart transplantation, valve repair
and ICD. Summary statistics included: Patient disposition and
location after 1 year, total estimated costs (including where
accrued) and hospitalisation rates due to CHF. RESULTS: Over
one year, 878,000 existing CHF patients plus 63,000 new cases
would cost the NHS £896 million. The total spend (and per-
centage) on patients in hospital, at home and in nursing homes
were £550 million (62%), £298 million (33%) and £47 million
(5%) respectively. Surgery accounted for £13 million of hospital
costs. Of 941,000 CHF patients, 291,000 will be hospitalised
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due to CHF within the year and of these, over 36,930 will be
readmitted within 2 months, (14,284 within 30 days). The
annual hospitalisation rate ranged from 12% (NYHA stage I) to
88% (NYHA stage IV). Excluding surgery, the £536 million
spent on CHF in hospitals is comprised of £171 million in A&E
(including paramedic and ambulance costs), £314 million in
general ward costs and £51 million in specialist ward costs.
CONCLUSIONS: The cost of CHF to the NHS is considerable,
with over 60% falling on hospital budgets and 40% of the total
cost (£355 million) being ward costs.
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OBJECTIVE: To investigate factors inﬂuencing initial pharma-
cotherapy for patients with dyslipidemia in primary care setting.
METHODS: Dyslipidemia patients were identiﬁed from a large
US national database of electronic medical records containing
diagnosis, lab and medication information in primary care
setting from 1997 to 2004. Initial pharmacotherapy was deﬁned
as the 1st-antidyslipidemics prescribed if no antidyslipidemics
were given 12-month prior to the initiation. Logistic regression
models used to examine impact of patient demographics, 
clinical characteristics, and comorbidities on three outcomes:
whether 1) any antidyslipidemics; 2) statin in particular; or 3)
combination therapy was initiated. RESULTS: Total 16,578
patients included in analysis. Male and older patients were more
likely to initiate any antidyslipidemics than females (odds ratio
(OR): 1.14) and younger patients (OR: 3.72 for over 65- vs.
under 40-years). Higher LDL-C and triglyceride (TG), and lower
HDL-C were associated with higher probability of initiating any
antidyslipidemics. Patients with coronary heart disease (CHD)
(OR: 1.60), diabetes (OR: 2.42), hypertension (OR: 1.19), other
atherosclerotic disease (OR: 1.52), and obesity (OR: 1.10) were
more likely to initiate any antidyslipidemics than those didn’t
have those co-morbidities. Among patients who started phar-
macotherapy, those with higher LDL-C or CHD or diabetes were
more likely to be on a statin; however, lower HDL-C and higher
TG were associated with lower likelihood of initiating a statin.
Higher TG level (500+ mg/dL) was the only signiﬁcant predictor
for use of combination therapy among antidyslipidemic users at
diagnosis. CONCLUSIONS: High LDL-C, CHD and diabetes
were strong predictors of initiating any antidyslipidemic agents,
and statins in particular for patients with dyslipidemia. That
patients with abnormal HDL-C or TG were less likely to use
statins might reﬂect perceptions about ineffectiveness of statins
in treating these abnormalities. Further studies are needed to
assess long-term use patterns of antidyslipidemics and associated
outcomes in clinical practice.
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OBJECTIVES: To investigate the clinical efﬁcacy of rosuvastatin
in low-density lipoprotein (LDL) lowering therapy, to investigate
the side effect proﬁle of rosuvastatin as compared to other
statins, and to compare the cost of LDL lowering therapy using
rosuvastatin and other statins. METHODS: This study was a ret-
rospective study in patients who took rosuvastatin in the outpa-
tient clinics of Prince of Wales Hospital during the period of July
1, 2004–June 30, 2005. The prescribing pattern, the utilization
pattern and the side effect proﬁle were recorded. Descriptive sta-
tistics were used and continuous data were reported as mean ±
SD. Lipid proﬁle of each patient was examined according to the
ATPIII guidelines. RESULTS: A total of 261 patients (mean age:
64.8 ± 12 years old; 55.6% male) were recruited in the study.
The baseline mean LDL levels were 3.49 ± 1.30 mmol/L prior to
rosuvastatin and 2.25 ± 1.68 mmol/L after treatment. Rosuvas-
tatin raised the LDL goal attainment rate from 28.0% to 74.3%
and the mean percentage reductions of LDL and triglycerides
(TG) were 35.5% and 10.6% respectively. Approximately 4%
of patient had developed side effects including myalgia, elevated
liver enzyme, and dizziness. Only 17.2% of patients had lipid
assessment within 6 weeks and 47.9% had Liver Function Test
(LFT) within 3 months. Nine percent and 13.8% of patients
respectively had never received these tests. The cost of rosuvas-
tatin was between that of the 2 most commonly prescribed
statins, atorvastatin and simvastatin, in Hong Kong. CONCLU-
SION: Rosuvastatin was effective in LDL goal attainment and
lowering of LDL and TG. Liver enzyme and creatine kinase
should be closely monitored in order to use the drug safely. Local
statin utilization guidelines should be established and reinforced
to promote proper use of lipid lowering agents that may lead to
better clinical and economic outcomes.
PCV63
DEVELOPING HOSPICE DRUG FORMULARIES USING MULTI-
ATTRIBUTE UTILITY THEORY (MAUT) METHOD AND THE
EVALUATION OF THEIR ECONOMIC IMPACT
Khandelwal NG1, Krueger KP2, Berger BA1, Carpenter M1,
Butz B3
1Auburn University, Auburn, AL, USA, 2University of Wyoming,
Laramie, WY, USA, 3Hospice of East Alabama Medical Center, Auburn,
AL, USA
OBJECTIVES: Hospices in the U.S are burdened with increas-
ing pharmaceutical costs and therefore should implement drug
formulary as a cost-containment tool. The study aimed at devel-
oping rational hospice formularies for congestive heart failure
and depression conditions based on Multi-Attribute Utility
Theory (MAUT) methodology. Economic impact of the formu-
laries developed in this study was also investigated. METHOD:
MAUT is a systematic method that assists the P&T committee
in selecting appropriate drugs by assessing four drug attributes:
efﬁcacy, safety, cost, and dosage-form related parameters. For
each therapeutic class, members of the P&T committee ranked
and weighted their preferences for different drug attributes and
factors considered important for the ﬁnal drug selection. The
preference values were combined with literature-based factor
values for each drug obtained through systematic literature
review process to give total utility score values for that drug.
Within each therapeutic class, drugs with highest total utility
scores were selected for the formulary. For economic impact eval-
uation, three categories of drug costs (i.e. total drug costs; spe-
ciﬁc-drug costs; and other drug costs related to the condition)
were computed and compared across pre and post-formulary
groups. RESULT: In each condition, all three types of drug costs
were found to be lower in the post-formulary group as compared
to the pre-formulary groups, however, these were not found to
be statistically signiﬁcant. After adjusting for the price differen-
tials, post hoc analyses for the formulary agents showed that on
a per patient day level, about 8 cents and about 44 cents was
saved as a result of implementing depression and CHF formula-
ries respectively. CONCLUSION: The MAUT method was
found to be a useful decision-making tool that assisted in suc-
